← All trials
NCT01748721
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2013
- Primary completion
- May 1, 2015
- Completion date
- May 1, 2015
- First posted
- —
- Last posted
- —
- Enrollment
- 27
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- MorphotekLead sponsor
- National Cancer Institute (NCI)Collaborator
- National Cancer Institute (NCI)Overall official - principal investigator
Drugs studied
Indications studied
- Burkitt Lymphoma
- Hodgkin Disease
- Leukemia, Hairy Cell
- Lymphoma
- Lymphoma, Follicular
- Lymphoma, Non-Hodgkin
- Lymphomatoid Granulomatosis
- Waldenstrom Macroglobulinemia
- Neoplasms
- Sezary Syndrome
- Testicular Neoplasms
- Transplantation
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia-Lymphoma, Adult T-Cell
- Lymphoma, T-Cell
- Lymphoma, Large-Cell, Immunoblastic
- Lymphoma, Large B-Cell, Diffuse
- Lymphoma, T-Cell, Peripheral
- Lymphoma, Large-Cell, Anaplastic
- Lymphoma, B-Cell, Marginal Zone
- Lymphoma, Mantle-Cell
- Leukemia, Large Granular Lymphocytic
- Intraocular Lymphoma
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.